Results 211 to 220 of about 589,804 (355)
Challenges and advances in the assessment of the disposition of antibody‐drug conjugates [PDF]
Amrita V. Kamath, Suhasini Iyer
openalex +1 more source
Harnessing ExDNA for precision exatecan delivery in cancer: a novel antibody-drug conjugate approach. [PDF]
Ianniello Z+8 more
europepmc +1 more source
Platinum‐Copper bimetallic nanoparticles may evolve depending on their synthesis under tumor microenvironment conditions and play a dual role as chemotherapeutic agents after releasing Cu ions and as near infrared photothermal agents with the Pt‐rich remaining frames.
Jose I. Garcia‐Peiro+7 more
wiley +1 more source
Harnessing computational technologies to facilitate antibody-drug conjugate development. [PDF]
Croitoru A, Orr AA, MacKerell AD.
europepmc +1 more source
High-efficiency gene transfer by adenovirus coupled to DNA-polylysine complexes [PDF]
Agarwal, Santosh+7 more
core +1 more source
Adalimumab‐Poloxamer Conjugate for Bio‐Better: Enhanced Stability and Function
Antibody‐polymer conjugates, particularly poloxamer conjugates, enhance antibody stability by improving tolerance to physicochemical stress and attenuating proteolysis by proteases. Furthermore, the higher affinity observed with poloxamer conjugation compared to standard PEGylation results in improved therapeutic efficacy in rheumatoid arthritis mouse ...
Jaewon Roh+3 more
wiley +1 more source
In this study, a physically enhanced vascular dECM bioink and used 3D‐coaxial bioprinting are developed to fabricate mature brain blood vessels for cerebral atherosclerosis research. This model demonstrates that vascular geometry‐induced hemodynamic changes trigger vascular inflammation, ensuring its potential for cerebrovascular research.
Wonbin Park+7 more
wiley +1 more source
The Impact of Conjugation Mode and Site on Tubulysin Antibody-Drug-Conjugate Efficacy and Stability. [PDF]
Yamazoe S+13 more
europepmc +1 more source
This study presents a microfluidic brain microvascular network‐on‐chip (BMVasChip) to investigate endothelial barrier dysfunction caused by flavivirus non‐structural protein 1 (NS1), including virus‐ and time‐dependent vascular damage, leakiness, and dysfunction.
Monika Rajput+5 more
wiley +1 more source